Attovia Therapeutics (NASDAQ:ATTO) Director Colin Walsh Sells 105,807 Shares

Attovia Therapeutics, Inc. (NASDAQ:ATTO) Director Colin Walsh sold 105,807 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $21.28, for a total transaction of $2,251,572.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Colin Walsh also recently made the following trade(s):

• On Thursday, August 6th, Colin Walsh acquired 500,000 shares of Attovia Therapeutics stock. The stock was bought at an average cost of $17.00 per share, with a total value of $8,500,000.00.

Attovia Therapeutics Stock Performance

Attovia Therapeutics stock opened at $19.18 on Friday. Attovia Therapeutics, Inc. has a 1 year low of $16.15 and a 1 year high of $22.79.

Institutional Trading of Attovia Therapeutics

An institutional investor recently raised its position in Attovia Therapeutics stock. BlackRock Inc. increased its position in Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.